The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Many ways to resistance: How melanoma cells evade targeted therapies
Open accessAbstract
Melanoma is an aggressive malignancy originating from pigment-producing melanocytes. The development of targeted therapies (MAPK pathway inhibitors) and immunotherapies (immune checkpoint inhibitors) led to a substantial improvement in overall survival of patients. However, the long-term efficacy of such treatments is limited by side effects, lack of clinical effects and the rapidly emerging resistance to treatment. A number of molecular mechanisms underlying this resistant phenotype have already been elucidated. In this review, we summarise currently available treatment options for metastatic melanoma and the known resistance mechanisms to targeted therapies. A focus will be placed on "phenotype switching" as a mechanism and driver of drug resistance, together with an overview of novel approaches to circumvent resistance. A large body of recent data and literature suggests that tumour progression and phenotype switching could be better controlled and development of resistance prevented or at least delayed, by combining drugs targeting fast- and slow-proliferating cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells
Fisher, M. L., Grun, D., Adhikary, G., Xu, W., & Eckert, R. L. (2017) · Oncotarget · doi:10.18632/oncotarget.22628 · Cited by 82
RetractedImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Regulation of microRNA function in animals
Gebert, L. F. R., & MacRae, I. J. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0045-7 · Cited by 2,284
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218
MITF: master regulator of melanocyte development and melanoma oncogene
Levy, C., Khaled, M., & Fisher, D. E. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.008 · Cited by 1,169
Roesch, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabierowski, S. E., Brafford, P. A., Vultur, A., Basu, D., Gimotty, P., Vogt, T., & Herlyn, M. (2010) · Cell · doi:10.1016/j.cell.2010.04.020 · Cited by 1,158
Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,022
Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., Wong, D. J. L., Atefi, M., Shirazi, R., Wang, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.017 · Cited by 938
Shain, A. H., & Bastian, B. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.37 · Cited by 896
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818
The role of BRAF V600 mutation in melanoma
Ascierto, P. A., Kirkwood, J. M., Grob, J.-J., Simeone, E., Grimaldi, A. M., Maio, M., Palmieri, G., Testori, A., Marincola, F. M., & Mozzillo, N. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-85 · Cited by 801
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Domingues, B., Lopes, J., Soares, P., & Populo, H. (2018) · ImmunoTargets and Therapy · doi:10.2147/itt.s134842 · Cited by 701
Roesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., Körbel, C., Laschke, M. W., Gimotty, P. A., Philipp, S. E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.003 · Cited by 670
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness
Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K. S., Testori, A., Larue, L., & Goding, C. R. (2006) · Genes & Development · doi:10.1101/gad.406406 · Cited by 608
The extracellular matrix and transforming growth factor-β1: Tale of a strained relationship
Hinz, B. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.05.006 · Cited by 608
Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Bastholt, L., Grob, J.-J., Malvehy, J., Newton-Bishop, J., Stratigos, A. J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.005 · Cited by 605
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 600
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592
Treatment of metastatic melanoma: an overview.
Bhatia, S., Tykodi, S. S., & Thompson, J. A. (2009) · PubMed · Cited by 537
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O., Kim, J. W., Cooper, Z. A., Piris, A., Frederick, D. T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0424 · Cited by 535
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state
Verfaillie, A., Imrichova, H., Atak, Z. K., Dewaele, M., Rambow, F., Hulselmans, G., Christiaens, V., Svetlichnyy, D., Luciani, F., Van den Mooter, L., et al. (2015) · Nature Communications · doi:10.1038/ncomms7683 · Cited by 489
YAP/TAZ Are Mechanoregulators of TGF-β-Smad Signaling and Renal Fibrogenesis
Szeto, S. G., Narimatsu, M., Lu, M., He, X., Sidiqi, A. M., Tolosa, M. F., Chan, L., De Freitas, K., Bialik, J. F., Majumder, S., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015050499 · Cited by 462
New perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
Moriceau, G., Hugo, W., Hong, A., Shi, H., Kong, X., Yu, C. C., Koya, R. C., Samatar, A. A., Khanlou, N., Braun, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.018 · Cited by 345
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
Wang, L., Leite de Oliveira, R., Huijberts, S., Bosdriesz, E., Pencheva, N., Brunen, D., Bosma, A., Song, J.-Y., Zevenhoven, J., Los-de Vries, G. T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.012 · Cited by 327
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Eroglu, Z., & Ribas, A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015616934 · Cited by 316
Sox10 regulates the development of neural crest-derived melanocytes in Xenopus
Aoki, Y., Saint-Germain, N., Gyda, M., Magner-Fink, E., Lee, Y.-H., Credidio, C., & Saint-Jeannet, J.-P. (2003) · Developmental Biology · doi:10.1016/s0012-1606(03)00161-1 · Cited by 270
Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance
Cerezo, M., Lehraiki, A., Millet, A., Rouaud, F., Plaisant, M., Jaune, E., Botton, T., Ronco, C., Abbe, P., Amdouni, H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.013 · Cited by 261
Smith, M. P., Brunton, H., Rowling, E. J., Ferguson, J., Arozarena, I., Miskolczi, Z., Lee, J. L., Girotti, M. R., Marais, R., Levesque, M. P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.003 · Cited by 246
Boshuizen, J., Koopman, L. A., Krijgsman, O., Shahrabi, A., van den Heuvel, E. G., Ligtenberg, M. A., Vredevoogd, D. W., Kemper, K., Kuilman, T., Song, J.-Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4472 · Cited by 229
AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma
Xu, M. Z., Chan, S. W., Liu, A. M., Wong, K. F., Fan, S. T., Chen, J., Poon, R. T., Zender, L., Lowe, S. W., Hong, W., et al. (2011) · Oncogene · doi:10.1038/onc.2010.504 · Cited by 228
Su, Y., Wei, W., Robert, L., Xue, M., Tsoi, J., Garcia-Diaz, A., Homet Moreno, B., Kim, J., Ng, R. H., Lee, J. W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712064115 · Cited by 228
Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm.
Wang, C., Zhu, X., Feng, W., Yu, Y., Jeong, K., Guo, W., Lu, Y., & Mills, G. B. (2016) · Europe PMC (PubMed Central) · Cited by 225
TGF-β Synergizes with Defects in the Hippo Pathway to Stimulate Human Malignant Mesothelioma Growth
Fujii, M., Toyoda, T., Nakanishi, H., Yatabe, Y., Sato, A., Matsudaira, Y., Ito, H., Murakami, H., Kondo, Y., Kondo, E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111653 · Cited by 224
Pinner, S., Jordan, P., Sharrock, K., Bazley, L., Collinson, L., Marais, R., Bonvin, E., Goding, C., & Sahai, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0781 · Cited by 202
Dabrafenib and its potential for the treatment of metastatic melanoma
Murali, R., Menzies, A. M., & Long, G. V. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s38998 · Cited by 192
The Role of PGC1α in Cancer Metabolism and its Therapeutic Implications
Tan, Z., Luo, X., Xiao, L., Tang, M., Bode, A. M., Dong, Z., & Cao, Y. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0621 · Cited by 189
Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors
Mulcahy Levy, J. M., Zahedi, S., Griesinger, A. M., Morin, A., Davies, K. D., Aisner, D. L., Kleinschmidt-DeMasters, B., Fitzwalter, B. E., Goodall, M. L., Thorburn, J., et al. (2017) · eLife · doi:10.7554/elife.19671 · Cited by 175
A novel class of microRNA-recognition elements that function only within open reading frames
Zhang, K., Zhang, X., Cai, Z., Zhou, J., Cao, R., Zhao, Y., Chen, Z., Wang, D., Ruan, W., Zhao, Q., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0136-3 · Cited by 173
Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Menzies, A. M., & Long, G. V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2054 · Cited by 170
Miller, M. A., Oudin, M. J., Sullivan, R. J., Wang, S. J., Meyer, A. S., Im, H., Frederick, D. T., Tadros, J., Griffith, L. G., Lee, H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0933 · Cited by 166
miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma
Díaz‐Martínez, M., Benito-Jardón, L., Alonso, L., Koetz‐Ploch, L., Hernando, E., & Teixidó, J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1318 · Cited by 164
YAP/TAZ Activation as a Target for Treating Metastatic Cancer
Warren, J., Xiao, Y., & Lamar, J. (2018) · Cancers · doi:10.3390/cancers10040115 · Cited by 164
Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway
Ehmer, U., & Sage, J. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0305 · Cited by 163
Ahmed, F., & Haass, N. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00173 · Cited by 155
Encorafenib and Binimetinib: First Global Approvals
Shirley, M. (2018) · Drugs · doi:10.1007/s40265-018-0963-x · Cited by 149
Microenvironment-derived factors driving metastatic plasticity in melanoma
Kim, I. S., Heilmann, S., Kansler, E. R., Zhang, Y., Zimmer, M. A., Ratnakumar, K., Bowman, R. L., Simon-Vermot, T., Fennell, M., Garippa, R. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14343 · Cited by 142
Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing
Miskolczi, Z., Smith, M. P., Rowling, E. J., Ferguson, J., Barriuso, J., & Wellbrock, C. (2018) · Oncogene · doi:10.1038/s41388-018-0209-0 · Cited by 135
Han, J., Bae, J., Choi, C., Choi, S.-P., Kang, H.-S., Jo, E., Park, J., Lee, Y. S., Moon, H., Park, C., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1235124 · Cited by 128
Zheng, X., Vis, D. J., Bruna, A., Šuštić, T., van Wageningen, S., Batra, A. S., Rueda, O. M., Bosdriesz, E., Caldas, C., Wessels, L. F. A., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0044-4 · Cited by 126
Endothelial Cells Promote Pigmentation through Endothelin Receptor B Activation
Regazzetti, C., Donatis, G. M. D., Ghorbel, H. H., Cardot‐Leccia, N., Ambrosetti, D., Bahadoran, P., Chignon‐Sicard, B., Lacour, J. ‐., Ballotti, R., Mahns, A., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.332 · Cited by 121
Irvine, M., Stewart, A., Pedersen, B., Boyd, S. C., Kefford, R. F., & Rizos, H. (2018) · Oncogenesis · doi:10.1038/s41389-018-0081-3 · Cited by 120
MicroRNAs in melanoma development and resistance to target therapy
Fattore, L., Costantini, S., Malpicci, D., Ruggiero, C. F., Ascierto, P. A., Croce, C. M., Mancini, R., & Ciliberto, G. (2017) · Oncotarget · doi:10.18632/oncotarget.14763 · Cited by 116
AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma
Zuo, Q., Liu, J., Huang, L., Qin, Y., Hawley, T. S., Seo, C., Merlino, G. T., & Yu, Y. (2018) · Oncogene · doi:10.1038/s41388-018-0205-4 · Cited by 115
Goodall, M. L., Wang, T., Martin, K. R., Kortus, M. G., Kauffman, A. L., Trent, J. M., Gately, S. T., & MacKeigan, J. P. (2014) · Autophagy · doi:10.4161/auto.28594 · Cited by 112
Cesi, G., Walbrecq, G., Zimmer, A. D., Kreis, S., & Haan, C. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0667-y · Cited by 111
Self-citationEffect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma
Smith, M. P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A., Hurlstone, A. F. L., & Wellbrock, C. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs471 · Cited by 110
Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
Wang, J., Huang, S. K., Marzese, D. M., Hsu, S. C., Kawas, N. P., Chong, K. K., Long, G. V., Menzies, A. M., Scolyer, R. A., Izraely, S., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.418 · Cited by 103
miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma
Stark, M. S., Bonazzi, V., Boyle, G. M., Palmer, J. M., Symmons, J., Lanagan, C. M., Schmidt, C., Herington, A. C., Ballotti, R., Pollock, P. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3924 · Cited by 102
Martin, S., Dudek-Perić, A. M., Garg, A. D., Roose, H., Demirsoy, Ş., Eygen, S. V., Mertens, F., Vangheluwe, P., Vankelecom, H. E. J., & Agostinis, P. (2017) · Autophagy · doi:10.1080/15548627.2017.1332550 · Cited by 96
A slow-cycling subpopulation of melanoma cells with highly invasive properties
Perego, M., Maurer, M., Wang, J., Shaffer, S. M., Müller, A. C., Parapatics, K., Li, L., Hristova, D. M., Shin, S. A., Keeney, F., et al. (2017) · Oncogene · doi:10.1038/onc.2017.341 · Cited by 87
Eggermont, A. M. M., Suciu, S., Rutkowski, P. L., Kruit, W., Punt, C. J. A., Dummer, R., Salès, F., Keilholz, U., de Schaetzen, G., & Testori, A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.014 · Cited by 86
Endothelin Promotes Colorectal Tumorigenesis by Activating YAP/TAZ
Wang, Z., Liu, P., Zhou, X., Wang, T., Feng, X., Sun, Y.-P., Xiong, Y., Yuan, H.-X., & Guan, K. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3229 · Cited by 85
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
Smith, M. P., Rowling, E. J., Miskolczi, Z., Ferguson, J., Spoerri, L., Haass, N. K., Sloss, O., McEntegart, S., Arozarena, I., von Kriegsheim, A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607156 · Cited by 77
New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
Brighton, H. E., Angus, S. P., Bo, T., Roques, J., Tagliatela, A. C., Darr, D. B., Karagoz, K., Sciaky, N., Gatza, M. L., Sharpless, N. E., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1653 · Cited by 75
Vitiello, M., Tuccoli, A., D’Aurizio, R., Sarti, S., Giannecchini, L., Lubrano, S., Marranci, A., Evangelista, M., Peppicelli, S., Ippolito, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15915 · Cited by 73
Gruosso, T., Garnier, C., Abélanet, S., Kieffer, Y., Lemesre, V., Bellanger, D., Bièche, I., Marangoni, E., Sastre‐Garau, X., Mieulet, V., et al. (2015) · Nature Communications · doi:10.1038/ncomms9583 · Cited by 72
Fattore, L., Ruggiero, C. F., Pisanu, M. E., Liguoro, D., Cerri, A., Costantini, S., Capone, F., Acunzo, M., Romano, G., Nigita, G., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0205-5 · Cited by 69
A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells
Cesi, G., Philippidou, D., Kozar, I., Kim, Y. J., Bernardin, F., van Niel, G., Wienecke-Baldacchino, A. K., Felten, P., Letellier, E., Dengler, S., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0886-x · Cited by 67
Self-citationCierlitza, M., Chauvistré, H., Bogeski, I., Zhang, X., Hauschild, A., Herlyn, M., Schadendorf, D., VOGT, T. M., & Roesch, A. (2014) · Experimental Dermatology · doi:10.1111/exd.12613 · Cited by 56
BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
Vido, M. J., Le, K., Hartsough, E. J., & Aplin, A. E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.049 · Cited by 55
Dietrich, P., Kuphal, S., Spruß, T., Hellerbrand, C., & Bosserhoff, A. (2017) · Oncogene · doi:10.1038/onc.2017.391 · Cited by 54
Smith, M. P., Rana, S., Ferguson, J., Rowling, E. J., Flaherty, K. T., Wargo, J. A., Marais, R., & Wellbrock, C. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12741 · Cited by 49
Weng, C., Yu, C.-C., Kuo, M., Chen, B.-C., & Lin, C. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.030 · Cited by 47
Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib
Doudican, N. A., & Orlow, S. J. (2016) · Oncogene · doi:10.1038/onc.2016.214 · Cited by 46
Bright, R., Coventry, B. J., Eardley-Harris, N., & Briggs, N. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000149 · Cited by 45
Petrachi, T., Romagnani, A., Albini, A., Longo, C., Argenziano, G., Grisendi, G., Dominici, M., Ciarrocchi, A., & Dallaglio, K. (2016) · Oncotarget · doi:10.18632/oncotarget.14321 · Cited by 41
Choe, M. H., Yina, Y., Kim, J., Hwang, S.-G., Han, Y.-H., & Kim, J. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0698-3 · Cited by 41
The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma
Liu, X., Wu, J., Qin, H., & Xu, J. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0565-2 · Cited by 38
Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells
Kozar, I., Cesi, G., Margue, C., Philippidou, D., & Kreis, S. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.04.005 · Cited by 31
Self-citationKodet, O., Dvořánková, B., ⁄, B. B., ⁄, V. S. ⁄. K., ⁄, I. K., Štork, J., Kučera, J., Szabó, P., Strnad, H., ř, M. K. ⁄., et al. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3448 · Cited by 29
Xue, G., Kohler, R. S., Tang, F., Hynx, D., Wang, Y., Orso, F., Prêtre, V., Ritschard, R., Hirschmann, P., Cron, P. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18213 · Cited by 25
Vlčková, K., Vachtenheim, J., Réda, J., Horák, P., & Ondrušová, Ľ. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13506 · Cited by 23
Alrabadi, N., Gibson, N., Curless, K. L., Liang Cheng, C., Kuhar, M., Chen, S., Warren, S. J. P., & Alomari, A. K. (2018) · Modern Pathology · doi:10.1038/s41379-018-0161-0 · Cited by 23
Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice
Roh, M. R., Zheng, Z., Kim, H. S., Jeung, H., Rha, S. Y., & Chung, K. Y. (2013) · Melanoma Research · doi:10.1097/cmr.0b013e32835e7713 · Cited by 21
Rare, yet relevant tumor cells – A new twist to melanoma cell plasticity
Zingg, D., & Sommer, L. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12643 · Cited by 5
Cited by
Cancer immunotherapy: Pros, cons and beyond
Tan, S., Li, D., & Zhu, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109821 · Cited by 688
G-quadruplexes: a promising target for cancer therapy
Kosiol, N., Juranek, S., Brossart, P., Heine, A., & Paeschke, K. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01328-4 · Cited by 533
Vergani, E., Dugo, M., Cossa, M., Frigerio, S., Di Guardo, L., Gallino, G., Mattavelli, I., Vergani, B., Lalli, L., Tamborini, E., et al. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00601-1 · Cited by 39
Metadata
- Authors
- Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 1871
- Issue
- 2
- Pages
- 313-322
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W2912456393
- Cited by
- 270
- References
- 100
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.